Summary
The U.S. announced its financial support for a new HIV prevention drug called lenacapavir. This drug, which only needs to be taken twice a year, aims to reach 2 million people by 2028, especially in countries heavily affected by HIV/AIDS. The U.S. will work with these countries to prevent the spread of HIV and focus on reducing mother-to-child transmission.
Key Facts
- The U.S. is financially backing a new HIV prevention drug called lenacapavir.
- Lenacapavir is an injectable drug that only needs to be administered twice a year.
- The drug could reach up to 2 million people by 2028.
- The U.S. plans to help countries with major HIV/AIDS epidemics reduce virus transmission.
- Lenacapavir offers almost complete protection against contracting HIV, based on clinical trials.
- The initiative is in partnership with the Global Fund and Gilead Sciences.
- Results showed the drug could help prevent mother-to-child transmission of HIV.
- The U.S. leads global efforts against HIV/AIDS, largely through its PEPFAR program.
